Emcure Pharmaceuticals Share Price Today

Emcure Pharmaceuticals approves merger of two subsidiaries into parent entity

Emcure Pharmaceuticals board approved merger of Zuventus Healthcare and Emcutix Biopharmaceuticals. No consideration payable as both subsidiaries are wholly owned by the parent company. Zuventus Healthcare reported turnover of ₹1,040.58 crore for FY26. Emcutix Biopharmaceuticals reported negative net worth of ₹(13.07) crore. Scheme subject to NCLT Mumbai Bench approval under Companies Act, 2013.

Emcure Pharmaceuticals sees ₹28.98 crore NSE block trade

A block trade of approximately 152,544 shares of Emcure Pharmaceuticals was executed on the NSE. The trade was priced at ₹1,900.10 per share. Total value of the transaction amounted to ₹28.98 crore.

Emcure Pharmaceuticals faces ₹57.74 crore income-tax penalty for FY15-FY21

Emcure Pharmaceuticals received an aggregate income-tax penalty of ₹57.74 crore. The penalty covers financial years FY15 through FY21 (AY16 to AY22). The dispute was initiated by the Deputy Commissioner of Income Tax, Pune, on December 27, 2023. The company is evaluating legal remedies and intends to file an appeal before the Appellate Authority.

Emcure Pharmaceuticals FY26 Results: PAT up 33.1%, revenue crosses USD 1Bn+

Emcure Pharmaceuticals FY26 revenue from operations rose 16.6% YoY to INR 92,035 Mn, crossing USD 1Bn+. PAT grew 33.1% YoY to INR 9,413 Mn, with PAT margin expanding 120 bps to 10.2%. EBITDA rose 21.8% to INR 17,886 Mn; EBITDA margin improved 80 bps to 19.4%. Q1 FY27 revenue grew 22.8% YoY to INR 25,804 Mn; PAT up 36.2% YoY to INR 2,925 Mn. International revenue grew 22.2% YoY to INR 51,766 Mn, led by Europe at +25.5% to INR 18,498 Mn.

Emcure Pharma approves all AGM resolutions; Mehta reappointed for 5 years

All eight resolutions passed at Emcure Pharma's 45th AGM held on September 21, 2026. Satish Mehta reappointed as MD & CEO for five years from April 1, 2027, with 94.06% votes in favour. Final dividend of ₹3.60 per share ratified with 100% shareholder support. Public institutions cast 51.09% of their votes against Mehta's reappointment resolution. Raghu Kumar appointed as Independent Director for a three-year term effective August 6, 2026.

Emcure Pharmaceuticals to hold physical investor meet in Pune on Sep 4

Emcure Pharmaceuticals schedules physical investor meet in Pune. Event set for September 4, 2026, with institutional investors. Company confirms no unpublished price-sensitive info will be shared. Disclosure made under SEBI LODR Regulation 30 requirements.